ADENOSCAN Drug Patent Profile

✉ Email this page to a colleague

When do Adenoscan patents expire, and when can generic versions of Adenoscan launch?

Adenoscan is a drug marketed by Astellas and is included in one NDA.

The generic ingredient in ADENOSCAN is adenosine. There are twenty-six drug master file entries for this compound. Thirteen suppliers are listed for this compound. Additional details are available on the adenosine profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Adenoscan

A generic version of ADENOSCAN was approved as adenosine by HIKMA on June 16^th, 2004.

Sign Up

AI Research Assistant

Questions you can ask:

What is the 5 year forecast for ADENOSCAN?
What are the global sales for ADENOSCAN?
What is Average Wholesale Price for ADENOSCAN?

Summary for ADENOSCAN

US Patents:	0
Applicants:	1
NDAs:	1
Raw Ingredient (Bulk) Api Vendors:	161
Clinical Trials:	10
Patent Applications:	2,804
DailyMed Link:	ADENOSCAN at DailyMed

Drug patent expirations by year for ADENOSCAN

Recent Clinical Trials for ADENOSCAN

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
NYU Langone Health	N/A
National Heart, Lung, and Blood Institute (NHLBI)	Early Phase 1
University of Utah	Early Phase 1

See all ADENOSCAN clinical trials

Paragraph IV (Patent) Challenges for ADENOSCAN

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
ADENOSCAN	Injection	adenosine	3 mg/mL, 20 mL and 30 mL vials	020059	1	2005-04-18

US Patents and Regulatory Information for ADENOSCAN

+ Get email alerts for changes to this table

Glossary

Subscribe to access the full database, or Sign Up
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Astellas	ADENOSCAN	adenosine	SOLUTION;INTRAVENOUS	020059-001	May 18, 1995		DISCN	Yes	No	⤷ Sign Up	⤷ Sign Up				⤷ Sign Up
Astellas	ADENOSCAN	adenosine	SOLUTION;INTRAVENOUS	020059-002	May 18, 1995		DISCN	Yes	No	⤷ Sign Up	⤷ Sign Up				⤷ Sign Up
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Exclusivity Expiration

Expired US Patents for ADENOSCAN

Subscribe to access the full database, or Sign Up
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Astellas	ADENOSCAN	adenosine	SOLUTION;INTRAVENOUS	020059-001	May 18, 1995	⤷ Sign Up	⤷ Sign Up
Astellas	ADENOSCAN	adenosine	SOLUTION;INTRAVENOUS	020059-002	May 18, 1995	⤷ Sign Up	⤷ Sign Up
Astellas	ADENOSCAN	adenosine	SOLUTION;INTRAVENOUS	020059-001	May 18, 1995	⤷ Sign Up	⤷ Sign Up
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>Patent No.	>Patent Expiration

International Patents for ADENOSCAN

See the table below for patents covering ADENOSCAN around the world.

Subscribe to access the full database, or Sign Up
Country	Patent Number	Title	Estimated Expiration
Australia	613304		⤷ Sign Up
Australia	5065585		⤷ Sign Up
Japan	H10114684	DIAGNOSING AUXILIARY USEFUL FOR DIAGNOSIS OF MYOCARDIAL FAILURE	⤷ Sign Up
>Country	>Patent Number	>Title	>Estimated Expiration

AI Research Assistant

Questions you can ask:

Summary for ADENOSCAN

Recent Clinical Trials for ADENOSCAN

Paragraph IV (Patent) Challenges for ADENOSCAN

Make Better Decisions: Try a trial or see plans & pricing